Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 3:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 3,666 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
Drug
Lead sponsor
Nanjing IASO Biotechnology Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
BT062
Drug
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Conditions
Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions
Liposome-encapsulated Daunorubicin-Cytarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Interventions
Odronextamab, Lenalidomide, Rituximab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
9
States / cities
Los Angeles, California • Plantation, Florida • Indianapolis, Indiana + 6 more
Conditions
Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse, Severe Aplastic Anemia, Refractory, Non-severe Aplastic Anemia
Interventions
Dibotatug (DR-01)
Drug
Lead sponsor
Dren Bio
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
Duarte, California • Palo Alto, California • Miami, Florida + 7 more
Conditions
Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
Interventions
Laboratory Biomarker Analysis, Sargramostim, Wild-type Reovirus
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
10 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Interventions
Tumor associated antigen lymphocytes (TAA-T)
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
6 Months to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Selinexor, Hydroxyurea, Ara-C
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
60 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • Stanford, California + 20 more
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)
Interventions
MGCD0103 and Azacitidine
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Beech Grove, Indiana • Las Vegas, Nevada • New York, New York + 1 more
Conditions
IDH1 Mutation, Relapsed / Refractory AML
Interventions
Olutasidenib, Azacitidine (AZA)
Drug
Lead sponsor
Timothy Pardee
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Follicular Lymphoma
Interventions
Venetoclax, Bendamustine, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 12 more
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
ALT-801
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Multiple Myeloma
Interventions
Phase 1a: CWP232291, Phase 1b: CWP232291, Lenalidomide, Dexamethasone
Drug
Lead sponsor
JW Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
PI3K inhibitor BKM120, rituximab, Pharmacodynamics, Correlative studies
Drug · Biological · Other
Lead sponsor
Kami Maddocks, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Columbus, Ohio
Conditions
Refractory Melanoma
Interventions
CP-675,206
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
36
States / cities
Scottsdale, Arizona • Bentonville, Arkansas • Fayetteville, Arkansas + 26 more
Conditions
Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
Interventions
Pixantrone (BBR 2778), fludarabine, dexamethasone, rituximab
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
4
States / cities
Tucson, Arizona • Baltimore, Maryland • Albuquerque, New Mexico + 1 more
Conditions
Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
Interventions
Leukapheresis, Fludarabine, Cyclophosphamide, CD33-CAR-T Cell Infusion
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Relapsed Lymphomas, Refractory Lymphomas
Interventions
Vorinostat, Pegylated Liposomal Doxorubicin (PLD), Doxil
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Lymphoma, B-Cell
Interventions
CC-220, Polatuzumab vedotin, Rituximab, Tafasitamab, Gemcitabine, Cisplatin, Dexamethasone, Bendamustine, Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Sioux Falls, South Dakota
Conditions
Lymphoma
Interventions
cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Temple University
Other
Eligibility
15 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2000
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Leukemia
Interventions
LY2510924, Idarubicin, Cytarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
T-cell NHL (PTCL or CTCL)
Interventions
KK2223
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
14
States / cities
Duarte, California • Orange, California • Stanford, California + 11 more
Conditions
Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory, Primary Mediastinal Large B-Cell Lymphoma Recurrent, Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion, Leukapheresis
Drug · Procedure
Lead sponsor
Jennifer Crombie, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Conditions
Cancer
Interventions
MEDI-547
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Detroit, Michigan